CellCentric
Generated by Meeveem AI
"Pioneering oral p300/CBP inhibition to transform multiple myeloma treatment"
Cambridge
•51 - 250 Employees
•Biotechnology
About CellCentric
CellCentric develops inobrodib, an oral first-in-class small molecule inhibitor targeting the twin proteins p300 and CBP. By binding to their bromodomain, inobrodib disrupts cancer cell growth by reducing expression of genes like MYC and IRF4 that drive tumour progression. The drug is being evaluated in clinical trials for multiple myeloma and other specific cancers. Many new cancer treatments require significant hospitalisation. InoPd, inobrodib combined with standard backbone therapies, is designed for community settings, reducing healthcare burden while reaching wider patient populations. Oral delivery gives patients greater control over their treatment, addressing a key patient preference while maintaining clinical effectiveness.
Illustrative visual - may not reflect the actual offering.
Illustrative visual - may not reflect the actual offering.
52
Team Members
2003
Founded
Series C
Funding
Hybrid
Work Environment
Our Vision
A world where advanced cancer therapies are accessible, oral, and empower patients with control over their treatment journey.
Our Mission
Transforms outcomes for people living with multiple myeloma and other cancers as quickly and effectively as possible through developing inobrodib.